
    
      This is a 52-week, Phase 1, open-label, single center, proof of concept study of FDA-approved
      pioglitazone in adult patients with sporadic inclusion body myositis (sIBM). The trial
      consists of a 4-week screening period;16-week "lead-in" period during which all subjects are
      observed off-treatment. At Week 16, all subjects will be started on pioglitazone at a dose of
      30 mg daily. The dose will be uptitrated to a goal dose of 45 mg daily after 2 weeks; 32-week
      treatment period with all subjects on 45 mg daily dose of pioglitazone.
    
  